The effects of zoledronic acid on serum lipids in multiple myeloma patients

Alessandro Gozzetti, Luigi Gennari, Daniela Merlotti, Stefania Salvadori, Vincenzo De Paola, Annalisa Avanzati, Beatrice Franci, Elena Marchini, Monica Tozzi, Maria Stella Campagna, Ranuccio Nuti, Francesco Lauria, Giuseppe Martini

Research output: Contribution to journalArticle

Abstract

Nitrogen-containing bisphosphonates (N-BPs) inhibit osteoclast-mediated bone resorption and are widely used for tumor-associated osteolysis. The mechanism of action of these drugs has not been completely clarified, but it has been observed that N-BPs may inhibit squalene synthase or farnesyl pyrophosphate synthase. Zoledronic acid (ZA) represents a novel N-BP which also has antitumor activity. To explore the effects of ZA on serum lipids, we studied 26 patients with smoldering myeloma at diagnosis. Sixteen patients were treated with ZA (4 mg) at baseline and at months 1, 2, 4, and 6. The remaining 10 served as controls. In all subjects, total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and C-terminal telopeptide of type I collagen (CTX) were measured at baseline and after 1, 3, and 6 months. In treated patients, we observed a progressive and significant reduction of TC, with a maximum decrease of 13% at 6 months. Moreover LDL-C decreased by 21% at 6 months, while no significant difference was appreciated in HDL-C and TGs. Also, the indexes of cardiovascular risk improved after ZA administration: TC/HDL-C ratio progressively decreased by 17% and HDL-C/LDL-C ratio increased by 36%, showing an effect that appears to be cumulative. In conclusion, ZA given intravenously at high doses in patients with smoldering myeloma seems to be able to modify the lipid profile with an improvement of atherosclerotic risk index.

Original languageEnglish
Pages (from-to)258-262
Number of pages5
JournalCalcified Tissue International
Volume82
Issue number4
DOIs
Publication statusPublished - Apr 2008

    Fingerprint

Keywords

  • Multiple myeloma
  • Serum lipid
  • Zoledronic acid

ASJC Scopus subject areas

  • Endocrinology

Cite this

Gozzetti, A., Gennari, L., Merlotti, D., Salvadori, S., De Paola, V., Avanzati, A., Franci, B., Marchini, E., Tozzi, M., Campagna, M. S., Nuti, R., Lauria, F., & Martini, G. (2008). The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcified Tissue International, 82(4), 258-262. https://doi.org/10.1007/s00223-008-9123-8